← Leaderboards
David S Knopman
Mayo Clinic Coll Of Medicine, Rochester
$13,079,150
Attributed
$16,629,683
Total exposure
6
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.8M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$16,629,683 · 6
By mechanism
R01$7,961,796 · 2
P30$4,911,709 · 2
P50$2,967,832 · 1
U01$788,346 · 1
Top collaborators
- Clifford Jack10 shared
- Thomas H Mosley1 shared
Most similar at Mayo Clinic Coll Of Medicine, Rochester
Same institution · by research overlap
- Phillip A Low$10,116,600
- Paola Sandroni$614,937
- Tanis Jill Ferman$2,601,779
- Iftikhar J Kullo$21,946,679
- Eduardo Benarroch$757,740
Others in their field
Top investigators on “Alzheimer&Apos”
- Jose A Luchsinger · Columbia University Health Sciences$56,595,040
- Eric M Reiman · Banner Health$48,982,487
- Yadong Huang · J. David Gladstone Institutes$40,311,515
- Lindsay A. Farrer · Boston University Medical Campus$34,189,802
- David M Holtzman · Washington University$28,985,806
- Michael W Weiner · Northern California Institute Res &Educ$28,197,224
Research focus
Alzheimer&AposPersonsPositron-Emission TomographyS DiseaseBaseDementiaAmyloidDiagnosticImageImpaired CognitionBiological MarkersParticipantGrantMild Cognitive ImpairmentLewy Body DiseaseElderlyClinical DiagnosisCognitiveTau ProteinsCognition DisordersDiagnosisCognitive TestingEvaluationGenetic
Grant awards (27)
Clinical Core$729,913
P30 · FY2025 · AG · contact PI
Clinical Core$729,913
P30 · FY2024 · AG · contact PI
Clinical Core$720,382
P30 · FY2023 · AG · contact PI
Clinical Core$720,601
P30 · FY2022 · AG · contact PI
Brain Aging and Alzheimer's Biomarker Classification Using Amyloid PET, tau PET, and Neurodegeneration on MRI: Developing the ATN system$732,392
R01 · FY2021 · AG
Clinical Core$670,300
P30 · FY2021 · AG · contact PI
Brain Aging and Alzheimer's Biomarker Classification Using Amyloid PET, tau PET, and Neurodegeneration on MRI: Developing the ATN system$732,392
R01 · FY2020 · AG
Clinical Core$670,300
P30 · FY2020 · AG · contact PI
Brain Aging and Alzheimer's Biomarker Classification Using Amyloid PET, tau PET, and Neurodegeneration on MRI: Developing the ATN system$732,392
R01 · FY2019 · AG
Clinical Core$670,300
P30 · FY2019 · AG · contact PI
Brain Aging and Alzheimer's Biomarker Classification Using Amyloid PET, tau PET, and Neurodegeneration on MRI: Developing the ATN system$732,392
R01 · FY2018 · AG
Clinical Core$664,614
P50 · FY2018 · AG · contact PI
Brain Aging and Alzheimer's Biomarker Classification Using Amyloid PET, tau PET, and Neurodegeneration on MRI: Developing the ATN system$732,392
R01 · FY2017 · AG
Clinical Core$666,687
P50 · FY2017 · AG · contact PI
Clinical Core$551,080
P50 · FY2016 · AG · contact PI
Validating the New Criteria for Preclinical Alzheimer's disease$522,972
R01 · FY2016 · AG
ARIC Neurocognitive Study (ARIC-NCS) Renewal 2 of 5$788,346
U01 · FY2015 · HL
Clinical Core$534,371
P50 · FY2015 · AG · contact PI
Validating the New Criteria for Preclinical Alzheimer's disease$507,281
R01 · FY2015 · AG
Clinical Core$551,080
P50 · FY2014 · AG · contact PI
Validating the New Criteria for Preclinical Alzheimer's disease$548,125
R01 · FY2014 · AG
Validating the New Criteria for Preclinical Alzheimer's disease$521,028
R01 · FY2013 · AG
Validating the New Criteria for Preclinical Alzheimer's disease$551,354
R01 · FY2012 · AG
Frontotemporal degeneration: a basis for clinical trials$393,572
R01 · FY2006 · AG · contact PI
Frontotemporal degeneration: a basis for clinical trials$399,905
R01 · FY2005 · AG
Frontotemporal degeneration: a basis for clinical trials$397,360
R01 · FY2004 · AG
Frontotemporal degeneration: a basis for clinical trials$458,239
R01 · FY2003 · AG